← feed

Is NCT03639155 results overdue?

Yes — results are overdue. Primary completion was 2018-05-23; the FDAAA-801 reporting deadline (2019-05-23) passed 2632 days ago and no results are posted on ClinicalTrials.gov.

A Study in Evaluating Bioequivalence Between Test and Reference Formulations of Vadadustat Tablets in Healthy Adults

NCT IDNCT03639155 ↗
SponsorAkebia Therapeutics (INDUSTRY)
Public issuerAkebia Therapeutics, Inc. — AKBA (CIK 0001517022) best-effort name match, 95% conf — verify on EDGAR ↗
PhasePHASE1
StatusCOMPLETED
Primary completion2018-05-23 (ACTUAL)
Reporting deadline2019-05-23 (completion + 365d)
Days overdue2632
Results postedNo — check results tab ↗
FDA-regulateddrug: yes, device: no
ProvenanceFlagged overdue on 2026-06-21 · SHA-256 3ebd0f976bf4a15e… (hash-chained, tamper-evident)

Source of record: ClinicalTrials.gov NCT03639155. The reporting requirement is FDAAA 801 (Public Law 110-85 §801) and the Final Rule, 42 CFR Part 11.

⚠ Public-record facts from ClinicalTrials.gov — not a finding of violation, fraud, or non-compliance, and not legal or investment advice. Full disclaimer →